Generation of induced pluripotent stem cells (UCLi024-A) from a patient with argininosuccinate lyase deficiency carrying a homozygous c.437G > A (p.Arg146Gln) mutation

Stem Cell Res. 2024 Apr:76:103365. doi: 10.1016/j.scr.2024.103365. Epub 2024 Feb 28.

Abstract

Argininosuccinic aciduria (ASA) is a rare inherited metabolic disease caused by argininosuccinate lyase (ASL) deficiency. Patients with ASA present with hyperammonaemia due to an impaired urea cycle pathway in the liver, and systemic disease with epileptic encephalopathy, chronic liver disease, and arterial hypertension. A human induced pluripotent stem cell (iPSC) line from the fibroblasts of a patient with ASA with homozygous pathogenic c.437G > A mutation of hASL was generated. Characterization of the cell line demonstrated pluripotency, differentiation potential and normal karyotype. This cell line, called UCLi024-A, can be utilized for in vitro disease modelling of ASA, and design of novel therapeutics.

MeSH terms

  • Argininosuccinate Lyase / genetics
  • Argininosuccinic Aciduria* / genetics
  • Argininosuccinic Aciduria* / metabolism
  • Argininosuccinic Aciduria* / therapy
  • Homozygote
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Mutation / genetics

Substances

  • Argininosuccinate Lyase